REFMAL 449 DDU - CK-101-101
A PHASE 1/2 OPEN-LABEL SAFETY PHARMACOKINETIC AND EFFICACY STUDY OF ASCENDING DOSES OF ORAL CK-101 IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Lung NCSLC Non-Squamous, T790 EGFR mutated
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

REFMAL 452 DDU - 4020-01-001
A PHASE 1 DOSE EscALATION AND COHORT EXPANSION STUDY OF TSR-022 AN ANTI-TIM-3 MONOCLONAL ANTIBODY IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 463 DDU - I8S-MC-JUAB
A PHASE 1 STUDY OF A ERK1/2 INHIBITOR (LY3214996) ADMINISTERED ALONE OR IN COMBINATION WITH OTHER AGENTS IN ADVANCED CANCER
Cancer types: Colorectal, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma, braf, KRAS, CDK, NF1, NRAS
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 260 - CP-MGAH22-04
A PHASE 3 RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS. TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT
Cancer types: Breast ER+, Breast HER2+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 274 - INO-VT-464-CL-006
A PHASE 1/2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF SEVITERONEL IN SUBJECTS WITH ADVANCED BREAST CANCER
Cancer types: Breast ER+, Breast Triple Negative
Lines of therapy: 2nd Line Metastatic

CLL 31 - IPI-145-12
A STUDY OF IPI-145 AND OFATUMUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA PREVIOUSLY ENROLLED IN STUDY IPI-145-07 (CLL 30 ROLLOVER STUDY)
Cancer types: Lymphoma/Leukemia
Lines of therapy: Other

CLL 39 - UTX-TGR-204
A MULTI-CENTER OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF UBLITUXIMAB (TG-1101) IN COMBINATION WITH TGR-1202 FOR PATIENTS PREVIOUSLY ENROLLED IN PROTOCOL UTX-TGR-304
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 201 - GI 201
A PHASE II STUDY OF NAB-PACLITAXEL PLUS RAMUCIRUMAB FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH METASTATIC GASTROESOPHAGEAL CANCER
Cancer types: Esophageal, Gastric
Lines of therapy: 2nd Line Metastatic
GI 238 - CA209577
A RANDOMIZED MULTICENTER DOUBLE BLIND PHASE III STUDY OF ADJUVANT NIVOLUMAB OR PLACEBO IN SUBJECTS WITH RESECTED ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER
Cancer types: Esophageal
Lines of therapy: Adjuvant

GI 241 - CA209649
A RANDOMIZED MULTICENTER OPEN-LABEL PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUMAB OR NIVOLUMAB IN COMBINATION WITH OXALIPLATIN PLUS FLUOROPYRIMIDINE VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER
Cancer types: Esophageal, Gastric
Lines of therapy: 1st Line Metastatic - Locally Advanced

GI 245 - ISB-MC-JGDP
A PHASE 2 (RANDOMIZED DOUBLE-BLINDED) STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER
Cancer types: Pancreas/Biliary
Lines of therapy: 1st Line Metastatic - Locally Advanced

GI 247 - CanStem303C
A PHASE III STUDY OF BBI-608 IN COMBINATION WITH 5-FLUOROURACIL LEUCOVORIN IRINOTECAN (FOLFIRI) IN ADULT PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (CRC)
Cancer types: Colorectal
Lines of therapy: 2nd Line Metastatic

GU 134 - WO30070
A PHASE III MULTICENTER RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY
Cancer types: Bladder
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 135 - MK-3475-361-00
A PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF PEMBROLIZUMAB WITH OR WITHOUT PLATINUM-BASED COMBINATION CHEMOTHERAPY VERSUS CHEMOTHERAPY IN SUBJECTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Cancer types: Bladder
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 144 - D5082c00003
A PHASE III OPEN LABEL RANDOMISED CONTROLLED MULTI-CENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF SAVOLITINIB VERSUS SUNITINIB IN PATIENTS WITH MET-DRIVEN UNRESECTABLE/LOCALLY ADVANCED OR METASTATIC PAPILLARY RENAL CELL CARCINOMA (PRCC)
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GYN 72 - FRV-004
A RANDOMIZED MULTICENTER PHASE II TRIAL TO EVALUATE THE SAFETY EFFICACY AND IMMUNOGENICITY OF VACCINATION WITH FOLATE RECEPTOR ALPHA PEPTIDES ADMIXED WITH GM-CSF AS A VACCINE ADJUVANT VERSUS GM-CSF ALONE IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER
Cancer types: GYN
Lines of therapy: Adjuvant

HEMREF 35 DDU - 13-601
A PHASE I OPEN-LABEL MULTI-DOSE DOSE ESCALATION STUDY OF PRT062070 IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL NON HODGKIN LYMPHOMA (NHL)
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
<table>
<thead>
<tr>
<th>Clinical trial list downloaded from FLCancer.com</th>
</tr>
</thead>
<tbody>
<tr>
<td>Created on 9/6/2019 at 8:19 PM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical trial</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MULTI 05 DDU - RXDX-101-02</strong></td>
<td>AN OPEN-LABEL MULTICENTER GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOUR NTRK1/2/3 ROS1 OR ALK GENE REARRANGEMENTS</td>
</tr>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head &amp; Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor, NTRK or ROS mutations</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>2nd Line Metastatic, 3rd Line+ Metastatic</td>
</tr>
</tbody>
</table>

| **REFMAL 360 DDU - MGCD516-001** | A PHASE 1/1B STUDY OF MGCD516 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES |
| **Cancer types:** | Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor, CBL and AXL |
| **Lines of therapy:** | 2nd Line Metastatic, 3rd Line+ Metastatic |

| **REFMAL 367 DDU - ALRN-6924-1-01** | A PHASE II OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF ALRN-6924 IN PATIENTS WITH ADVANCED SOLID TUMORS EXPRESSING WILD-TYPE P53 PROTEIN |
| **Cancer types:** | Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Solid Tumor, Sarcoma, MOM2 |
| **Lines of therapy:** | 2nd Line Metastatic, 3rd Line+ Metastatic |

| **REFMAL 390 DDU - D6130C00001** | A PHASE I OPEN-LABEL MULTICENTRE DOSE ESCALATION STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF AZD2811 IN PATIENTS WITH ADVANCED SOLID TUMOURS |
| **Cancer types:** | Lung Small Cell |
| **Lines of therapy:** | 2nd Line Metastatic, 3rd Line+ Metastatic |

| **REFMAL 430 DDU - STML-401-0115** | A PHASE I STUDY OF SL 401 A REVERSIBLE INHIBITOR OF NUCLEAR EXPORT IN PATIENTS WITH ADVANCED SOLID TUMORS |
| **Cancer types:** | Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor |
| **Lines of therapy:** | 2nd Line Metastatic, 3rd Line+ Metastatic |

| **REFMAL 435 - D8730C00001** | A PHASE I, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ASCENDING DOSES OF AZD4635 BOTH AS MONOTHERAPY AND IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES |
| **Cancer types:** | Prostate |
| **Lines of therapy:** | 2nd Line Metastatic, 3rd Line+ Metastatic |

| **LUN 326 - CA209-384** | A DOSE FREQUENCY OPTIMIZATION TRIAL OF NIVOLUMAB 240 MG EVERY 2 WEEKS VS 480 MG EVERY 4 WEEKS IN ADVANCED OR METASTATIC NSCLC PATIENTS WHO RECEIVED 12 MONTHS OF NIVOLUMAB AT 3 MG/KG OR 240 MG EVERY 2 WEEKS |
| **Cancer types:** | Lung NCSLC Non-Squamous, Lung NCSLC Squamous |
| **Lines of therapy:** | 1st Line Metastatic - Locally Advanced, Other |

| **LYM 115 - BGB-3111-GA-101** | PHASE 1B STUDY TO ASSESS SAFETY, TOLERABILITY AND ANTITUMOR ACTIVITY OF THE COMBINATION OF BGB-3111 WITH OBINUTUZUMAB IN SUBJECTS WITH B-CELL LYMPHOID MALIGNANCIES |
| **Cancer types:** | Lymphoma/Leukemia |
| **Lines of therapy:** | 2nd Line Metastatic |

| **LYM 120 - UTX-TGR-205** | A PHASE 2B RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF THE COMBINATION OF UBLITUXIMAB + TGR-1202 WITH OR WITHOUT BENDAMUSTINE AND TGR-1202 ALONE IN PATIENTS WITH PREVIOUSLY TREATED NON-HODGKIN'S LYMPHOMA. |
| **Cancer types:** | Lymphoma/Leukemia |
| **Lines of therapy:** | 2nd Line Metastatic, 3rd Line+ Metastatic |

Created on 9/6/2019 at 8:19 PM
LYM 126 - PCYC-1141-CA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB, IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN TREATMENT NAIVE SUBJECTS WITH FOLLICULAR LYMPHOMA
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 305 - DS164C00001
PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF AZD9291/PALOBO IN PATIENTS WITH EGFR MUTATION POSITIVE STAGE IB-IIIA NSCLC FOLLOWING COMPLETE TUMOR RESECTION WITH OR WITHOUT ADJUVANT CHEMOTHERAPY
Cancer types: Lung NCSLC Non-Squamous
Lines of therapy: Adjuvant

MM 74 - NSMM-5001
AN OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PARTICIPANTS
Cancer types: Myeloma
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

MULTI 12 - CA209-627
AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES
Cancer types: GYN, Solid Tumor
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

PRO 02 - ML28897
PHASE 2A STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB, AND VISMODEGIB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

PRO 10 - PRO 10
STUDY TO ASSESS THE ACTIVITY OF MOLECULARLY MATCHED TARGETED THERAPIES (REGORAFENIB OR AFATINIB) IN SELECT TUMOR TYPES BASED ON GENOMIC ALTERATIONS
Cancer types: Bladder, Esophageal, Gastric, Head & Neck, Hepatocellular, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Pancreas/Biliary, Solid Tumor
Lines of therapy: 2nd Line Metastatic

REFMAL 383 - D6015C00001
A PHASE IB, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOUR ACTIVITY OF AZD1775 MONOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMOURS
Cancer types: Breast Triple Negative, GYN, Lung Small Cell, Solid Tumor
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 473 DDU - 1381.1
AN OPEN-LABEL, PHASE I TRIAL TO DETERMINE THE MAXIMUM TOLERATED DOSE AND INVESTIGATE SAFETY, PHARMACOKINETICS AND EFFICACY OF BI 754091 IN PATIENTS WITH ADVANCED SOLID TUMORS.
Cancer types: Tmb >10, Vulvar
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 283 - 15-102-14
A PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIANS CHOICE (TPC) IN PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE STABLE BRAIN METASTASES AND HAVE BEEN PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE
Cancer types: Breast ER+, Breast HER2+, Breast Triple Negative
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
LYM 122 - ACE-LY-308
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF BR ALONE VERSUS IN COMBINATION WITH ACALABRUTINIB (ACP-196) IN SUBJECTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA.
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

MPN 09 - PAC203
AN OPEN-LABEL, RANDOMIZED, PHASE 2 DOSE-FINDING STUDY OF PACRITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB
Cancer types: Myelofibrosis
Lines of therapy: 2nd Line Metastatic

REFMAL 495 DDU - D6520C00001
A PHASE 1, MULTICENTER DOSE-ESCALATION STUDY TO ASSESS THE TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF AZD5153 IN PATIENTS WITH RELAPSED/RECURRENT/METASTATIC SOLID TUMORS, INCLUDING LYMPHOMAS
Cancer types: GYN, ovarian
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 485 DDU - 1381.2
AN OPEN LABEL, PHASE I DOSE-FINDING STUDY OF BI 754111 AS MONOTHERAPY AND IN COMBINATION WITH BI 754091 IN PATIENTS WITH ADVANCED CANCER FOLLOWED BY EXPANSION COHORTS AT THE RPIID OF THE COMBINATION IN PATIENTS WITH NSCLC AND OTHER TUMOUR TYPES
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous, MSI High, tmb >10
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

CLL 41 - TGR-1202-201
EVALUATE THE EFFICACY AND SAFETY OF TGR-1202 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO ARE INTOLERANT TO PRIOR THERAPY
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic

GU 147 - WO39210
A STUDY OF ATEZOLIZUMAB AS ADJUVANT THERAPY IN PARTICIPANTS WITH RENAL CELL CARCINOMA (RCC) AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY (IMMOTION010)
Cancer types: Renal Cell
Lines of therapy: Adjuvant

REFMAL 520 DDU - CP-MGD013-01
A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION STUDY OF MGD013, A DUAL-AFFINITY RE-TARGETING (DART®) PROTEIN BINDING PD-1 AND LAG-3 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS
Cancer types: Breast HER2+, Hepatocellular, Lung Small Cell, DLBCL
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 506 DDU - mRNA-4157-P101
A PHASE 1, OPEN LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOCOMPETENCY OF MRNA-4157 ALONE IN SUBJECTS WITH RESECTED SOLID TUMORS AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH UNRESECTABLE SOLID TUMORS
Cancer types: Bladder, Breast Triple Negative, Esophageal, Gastric, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell, MSI High, tmb >10
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 350 - B7461006
A STUDY OF LORLATINIB VERSUS CRIZOTINIB IN FIRST LINE TREATMENT OF PATIENTS WITH ALK-POSITIVE NSCLC
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced
GU 142 - CO-338-052
A STUDY OF RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HOMOLOGOUS RECOMBINATION GENE DEFICIENCY
Cancer types: Prostate
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 358 - D419MC00004
THIS IS A PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, COMPARATIVE GLOBAL PHASE 3 STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF DURVALUMAB OR DURVALUMAB + TREMELIMUMAB IN COMBINATION THERAPY WITH PLATINUM BASED CHEMOTHERAPY FOR THE FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC).
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic · Locally Advanced

GYN 63 - PRO-105
A PHASE II OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF ACELARIN® (NUC-1031) GIVEN ON DAYS 1, 8 AND 15 OF A 28-DAY SCHEDULE IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER
Cancer types: GYN
Lines of therapy: Other

BRE 296 - I3Y-MC-JPCF
A STUDY TO COMPARE TREATMENT AFTER SURGERY OF ABEMACICLIB (LY2835219) COMBINED WITH STANDARD ENDOCRINE THERAPY VERSUS ENDOCRINE THERAPY ALONE IN PARTICIPANTS WITH BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: Adjuvant

BRE 297 - H3B-6545-A001-101
A PHASE I/II MULTICENTER, OPEN LABEL TRIAL OF H3B-6545, A COVALENT ANTAGONIST OF ESTROGEN RECEPTOR ALPHA, IN WOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 496 DDU - C-700-01
A PHASE 1/2, OPEN-LABEL, MULTIPLE ASCENDING DOSE TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, BIOLOGICAL, AND CLINICAL ACTIVITY OF AGEN2034 IN SUBJECTS WITH METASTATIC OR LOCALLY ADVANCED SOLID TUMORS, WITH EXPANSION TO SECOND-LINE CERVICAL CANCER
Cancer types: Cervical
Lines of therapy: 2nd Line Metastatic

REFMAL 505 DDU - 1379-0001
AN OPEN-LABEL PHASE I DOSE FINDING TRIAL WITH BI 891065 IN COMBINATION WITH BI 754091 TO CHARACTERISE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN PATIENTS WITH ADVANCED AND/OR METASTATIC MALIGNANCIES
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Neuroendocrine, Prostate, Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GU 150 - CX-839-005
CB-839 WITH EVEROLIMUS VS. PLACEBO WITH EVEROLIMUS IN PATIENTS WITH RCC
Cancer types: Renal Cell
Lines of therapy: 3rd Line+ Metastatic

BRE 297 - MO39196
A STUDY OF ATEZOLIZUMAB AND PACLITAXEL VERSUS PLACEBO AND PACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER
Cancer types: Breast Triple Negative
Lines of therapy: 1st Line Metastatic · Locally Advanced
GU 137 - E7080-G000-307
LENNATINIB/EVEROLIMUS OR LENNATINIB/PEMBOLOZUMAB VERSUS SUNITINIB ALONE AS TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Cancer types: Renal Cell
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 362 - BO29554
A STUDY TO EVALUATE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PARTICIPANTS WITH NON-SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 304 - MO39193
A STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT TRIPLE-NEGATIVE BREAST CANCER
Cancer types: Breast Triple Negative
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 549 DDU - 001-00
A PHASE 1 STUDY OF MK-5890 AS MONOTHERAPY AND IN COMBINATION WITH PEMBOLOZUMAB IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Other
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 256 DDU - TAK-931-2001
AN OPEN-LABEL, PHASE 2, PARALLEL ARM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND ACTIVITY OF TAK-931 SINGLE AGENT IN PATIENTS WITH METASTATIC PANCREATIC CANCER OR METASTATIC COLORECTAL CANCER
Cancer types: Esophageal, Lung NCSLC Squamous
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GU 151 DDU - TO-TAS3681-101
A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY OF TAS3681 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Cancer types: Prostate
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

HEMREF 41 DDU - D6130C00003
A PHASE I/II, OPEN-LABEL, MULTICENTRE 2-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF AZD2811 NANOPARTICLE IN PATIENTS WITH RELAPSED ACUTE MYELOID LEUKAEMIA/HIGH-RISK MYELODYSPLASTIC SYNDROME OR TREATMENT-NAÏVE PATIENTS NOT ELIGIBLE FOR INTENSIVE INDUCTION THERAPY
Cancer types: AML
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 303 - ODO-TE-B301
TESETAXEL PLUS REDUCED DOSE OF CAPECITABINE VS. CAPECITABINE IN HER2 NEGATIVE, HR POSITIVE, MBC
Cancer types: Breast ER+
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

LUN 371 - MK-3475-654
PEMBOLOZUMAB PLUS EPACADOSTAT VS PEMBOLOZUMAB PLUS PLACEBO IN METASTATIC NON-SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>LYM 135 - GO39942</td>
<td>A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH R-CHP VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)</td>
</tr>
<tr>
<td>HEMREF44 DDU - INCB 53914-101</td>
<td>A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF INCB053914 IN SUBJECTS WITH ADVANCED MALIGNANCIES</td>
</tr>
<tr>
<td>REFMAL 529 DDU - 3000-01-002</td>
<td>PHASE 1B DOSE-FINDING STUDY OF NIRAPARIB OR CARBOPLATIN-PACLITAXEL IN COMBINATION WITH TSR-042 IN PATIENTS WITH ADVANCED OR METASTATIC CANCER</td>
</tr>
<tr>
<td>LUN 372 - MK-3475-715</td>
<td>PEMBROLIZUMAB PLUS EPACADOSTAT ALONE OR WITH PLATINUM-BASED CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS PLATINUM-BASED CHEMOTHERAPY PLUS PLACEBO IN METASTATIC NON-SMALL CELL LUNG CANCER</td>
</tr>
<tr>
<td>GYN 78 - 3000-02-004</td>
<td>PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY</td>
</tr>
<tr>
<td>GI 258 - D419CC00002</td>
<td>STUDY OF DURVALUMAB AND TREMELIMUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA</td>
</tr>
<tr>
<td>GYN 80 - DEK-DKK1-P204</td>
<td>A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF DKN-01 (HUMANIZED MONOCLONAL ANTIBODY TO DKK1 ) AS A MONOTHERAPY OR IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH RELAPSED/ REFRACTORY ENDOMETRIOID ENDOMETRIAL OR ENDOMETRIOID OVARIAN CANCER</td>
</tr>
<tr>
<td>GI 266 - BGB-290-303</td>
<td>A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF BGB-290 ( PARP INHIBITOR ) VERSUS PLACEBO AS MAINTENANCE THERAPY IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER THAT RESPONDED TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY</td>
</tr>
</tbody>
</table>

**Cancer types:**
- Lymphoma/Leukemia
- Myelofibrosis
- Lung NSCLC Non-Squamous
- Lung NSCLC Squamous
- Bladder
- GYN
- Hepatocellular
- Bladder, GYN
- Bladder
- Gynecological
- Gastrointestinal

**Lines of therapy:**
- 1st Line Metastatic - Locally Advanced
- 2nd Line Metastatic, 3rd Line+ Metastatic
- 1st Line Metastatic - Locally Advanced
- 2nd Line Metastatic, 3rd Line+ Metastatic
- 1st Line Metastatic - Locally Advanced

**Created on 9/6/2019 at 8:19 PM**
**Clinical trial list downloaded from FLCancer.com**

**BRE 308 - 3000-01-005**

**STUDY EVALUATING THE ANTITUMOR ACTIVITY AND SAFETY OF NIRAPARIB AS NEOADJUVANT TREATMENT**

**Cancer types:** Breast ER+, Breast Triple Negative

**Lines of therapy:** Neo-Adjuvant

**MM 99 - C16047**

**STUDY OF IXAZOMIB+DARATUMUMAB+DEXAMETHASONE (IDD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)**

**Cancer types:** Myeloma

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LUN 385 - AM00010-201**

**A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NSCLC WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION**

**Cancer types:** Lung NSCLC Non-Squamous, Lung NSCLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**MDS 21 - P-3001**

**PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PARTICIPANTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (AML)**

**Cancer types:** Hematology/Other, MDS, AML

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**LUN 380 - GO40920**

**A STUDY OF MTIG7192A IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAÍVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER**

**Cancer types:** Lung NSCLC Non-Squamous, Lung NSCLC Squamous

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**LYM 138 DDU - ACE-LY-111**

**PRISM: A PLATFORM PROTOCOL FOR THE TREATMENT OF RELAPSED/REFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA**

**Cancer types:** Lymphoma/Leukemia, DLBCL

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 543 DDU - JAB-3068-01**

**A PHASE 1, MULTI-CENTER, DOSE ESCALATION, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF JAB-3068 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS**

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 560 DDU - BDB001-101**

**A PHASE 1 OPEN-LABEL DOSE ESCALATION STUDY OF BDB001 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS**

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 562 DDU - BDB001-101**

**A PHASE 1 OPEN-LABEL DOSE ESCALATION STUDY OF BDB001 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS**

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic
<table>
<thead>
<tr>
<th>REFMAL 563 DDU - 034-00</th>
<th>A PHASE II STUDY OF NAVARIXIN (MK-7123) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH SELECTED ADVANCED/METASTATIC SOLID TUMORS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Lung NCSLC Non-Squamous, Lung NCSLC Squamous</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>2nd Line Metastatic, 3rd Line+ Metastatic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LUN 386 - CAC288ST2301</th>
<th>A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF CANAKINUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN ADULT SUBJECTS WITH STAGES AJCC/UICC V. 8 II-IIIA AND IIIB (T&gt;5CM N2) COMPLETELY RESECTED (R0) NON- small cell lung cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Lung NCSLC Non-Squamous, Lung NCSLC Squamous</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>Adjuvant</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GI 261 - CA209-9X8</th>
<th>AN INVESTIGATIONAL IMMUNOTHERAPY STUDY OF NIVOLUMAB WITH STANDARD OF CARE THERAPY VS STANDARD OF CARE THERAPY FOR FIRST-LINE TREATMENT OF COLORECTAL CANCER THAT HAS SPREAD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Colorectal</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>1st Line Metastatic - Locally Advanced</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MM 90 - EFC12522</th>
<th>RANDOMIZED, OPEN LABEL STUDY ASSESSING THE CLINICAL BENEFIT OF SAR650984, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE COMBINATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR TRANSPLANT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Myeloma</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>1st Line Metastatic - Locally Advanced</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GI 268 - EF-27</th>
<th>EFFECT OF TUMOR TREATING FIELDS (TTFIELDS, 150 KHZ) AS FRONT-LINE TREATMENT OF LOCALLY-ADVANCED PANCREATIC ADENOCARCINOMA CONCOMITANT WITH GEMCITABINE AND NAB-Paclitaxel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Pancreas/Biliary</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>1st Line Metastatic - Locally Advanced</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GU 161 - CB-839-008</th>
<th>CB-839 WITH CABOZANTINIB VS. CABOZANTINIB WITH PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Renal Cell</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>2nd Line Metastatic, 3rd Line+ Metastatic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MM 90 - EFC12522</th>
<th>RANDOMIZED, OPEN LABEL STUDY ASSESSING THE CLINICAL BENEFIT OF SAR650984, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE COMBINATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR TRANSPLANT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Myeloma</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>1st Line Metastatic - Locally Advanced</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GI 261 - CA209-9X8</th>
<th>AN INVESTIGATIONAL IMMUNOTHERAPY STUDY OF NIVOLUMAB WITH STANDARD OF CARE THERAPY VS STANDARD OF CARE THERAPY FOR FIRST-LINE TREATMENT OF COLORECTAL CANCER THAT HAS SPREAD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Colorectal</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>1st Line Metastatic - Locally Advanced</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REFMAL 574 DDU - 64619178EDI1001</th>
<th>A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF JNJ-64619178, AN INHIBITOR OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) IN SUBJECTS WITH ADVANCED CANCERS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head &amp; Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Lymphoma/Leukemia, Melanoma, Prostate, Renal Cell</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>2nd Line Metastatic, 3rd Line+ Metastatic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GI 268 - EF-27</th>
<th>EFFECT OF TUMOR TREATING FIELDS (TTFIELDS, 150 KHZ) AS FRONT-LINE TREATMENT OF LOCALLY-ADVANCED PANCREATIC ADENOCARCINOMA CONCOMITANT WITH GEMCITABINE AND NAB-Paclitaxel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Pancreas/Biliary</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>1st Line Metastatic - Locally Advanced</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GU 162 - D933IC00003</th>
<th>STUDY OF DURVALUMAB ALONE AND DURVALUMAB+OLAPARIB IN ADVANCED, PLATINUM-INEligible BLADDER CANCER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Bladder</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>1st Line Metastatic - Locally Advanced</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GI 274 - M14-064</th>
<th>A STUDY OF ABT-165 PLUS FOLFIRI VS BEVACIZUMAB PLUS FOLFIRI IN SUBJECTS WITH METASTATIC COLORECTAL CANCER PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE/ OXALIPLATIN AND BEVACIZUMAB</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer types:</strong></td>
<td>Colorectal</td>
</tr>
<tr>
<td><strong>Lines of therapy:</strong></td>
<td>2nd Line Metastatic</td>
</tr>
</tbody>
</table>
REFMAL 507 DDU - TAB001-01
A PHASE I, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAB001 IN SUBJECTS WITH ADVANCED MALIGNANCIES

Cancer types: Esophageal, Gastric, Hepatocellular, Neuroendocrine, Sarcoma, GIST, Cholangiocarcinoma, Nasopharyngeal

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 585 DDU - RMC-4630-01
A PHASE I, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF RMC-4630 MONOTHERAPY IN ADULT PARTICIPANTS WITH RELAPSED/REFRACTORY SOLID TUMORS

Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Melanoma, Prostate, Renal Cell, MSI High, Tmb >10

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 578 DDU - KL166-I-01
A PHASE I-II, FIRST-IN-HUMAN STUDY OF KL166 IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC SOLID TUMORS WHICH ARE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE WHO DID NOT RESPOND OR STOPPED RESPONDING TO APPROVED THERAPIES AND PATIENTS WITH HER2 POSITIVE (BY IHC OR NS) OR LOW EXPRESSING (BY IHC) SOLID TUMORS WHO DID NOT RESPOND OR STOPPED RESPONDING TO APPROVED THERAPIES

Cancer types: Solid Tumor, Her 2 neu mutation

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 279 - MK7690-046
A PHASE II TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF VICRIVIROC (MK-7690) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH ADVANCED/METASTATIC MICROsatellite STABLE (MSS) COLORECTAL CANCER (CRC)

Cancer types: Colorectal

Lines of therapy: 3rd Line+ Metastatic

LYM 145 - RP6530-1602
AN OPEN LABEL, PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TENALISIB (RP6530), A NOVEL PI3K Ä/Ã DUAL INHIBITOR IN ADULT PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN’S LYMPHOMA (INHL)

Cancer types: Lymphoma/Leukemia

Lines of therapy: 3rd Line+ Metastatic

GU 164 - 516-003
PHASE 2 STUDY OF SITRAVATINIB AND NIVOLUMAB IN ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

Cancer types: Bladder

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 446 DDU - 204691
A PHASE I OPEN LABEL STUDY OF GSK3359609 ADMINISTERED ALONE AND IN COMBINATION WITH ANTICANCER AGENTS IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS

Cancer types: Bladder, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, MSI High

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 595 DDU - mRNA-2752-P101
A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF mRNA-2752, A LIPID NANOPARTICLE ENCAPSULATING MRNAS ENCODING HUMAN OX40L, IL-23, AND IL-36?, FOR INTRATUMORAL INJECTION ALONE AND IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE

Cancer types: Breast HER2+, Breast Triple Negative, Head & Neck, Melanoma

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 608 DDU - JTX-4014-101
PHASE 1 FIRST IN HUMAN STUDY OF PROGRAMMED CELL DEATH RECEPTOR-1 (PD-1) INHIBITOR MONOCLONAL ANTIBODY (MAB) JTX-4014 IN ADULT SUBJECTS WITH ADVANCED REFRACTORY SOLID TUMOR MALIGNANCIES

Cancer types: Bladder, Breast HER2+, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Melanoma, Prostate, Renal Cell, MSI High, Tmb >10

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
REFMAL 602 DDU - ADCT-601-101
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF ADCT-601 IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Breast Triple Negative, Colorectal, Esophageal, Gastric, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Mesothelioma, ovarian, Sarcoma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 312 - 1280-0022
XENTUZUMAB IN COMBINATION WITH EVEROLIMUS AND EXEMESTANE IN POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE AND HER2-NEGATIVE BREAST CANCER THAT HAS SPREAD
Cancer types: Breast ER+
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 541 DDU - 3000-01-004
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF NIRAPARIB TABLET FORMULATION COMPARED TO NIRAPARIB CAPSULE FORMULATION IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Breast Triple Negative, GYN, Prostate, BRCA mutated, ovarian
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LYM 150 DDU - LOXO-BTK-18001
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN'S LYMPHOMA (NHL)
Cancer types: Lymphoma/Leukemia, DLBCL, CLL/SLL
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MDS 24 - 04-30
CONTROLLED STUDY OF RIGOSERTIB VERSUS PHYSICIAN'S CHOICE OF TREATMENT IN MDS PATIENTS AFTER FAILURE OF AN HMA
Cancer types: Hematology/Other, MDS
Lines of therapy: 2nd Line Metastatic

LUN 396 - D9102C00001
STUDY OF DURVALUMAB+OLAPARIB OR DURVALUMAB AFTER TREATMENT WITH DURVALUMAB AND CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER
Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 617 DDU - KY1044-CT01
A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF KY1044 AS SINGLE AGENT AND IN COMBINATION WITH ANTI-PD-L1 (ATEZOLIZUMAB) IN ADULT PATIENTS WITH SELECTED ADVANCED MALIGNANCIES
Cancer types: Breast Triple Negative, Esophageal, Gastric, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Melanoma, Pancreas/Biliary, Renal Cell, Cervical
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 321 DDU - D8530C00001
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY OF AZD9833 ALONE OR IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH ER POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 605 DDU - PRT543-01
A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF PRT543 IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Melanoma, Prostate, Renal Cell, Solid Tumor, Myelofibrosis, MDS
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
Multi 36 DDU - EDP1503-101
A PHASE II OPEN LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF EDP1503 ALONE AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED METASTATIC COLORECTAL CARCINOMA, TRIPLE-NEGATIVE BREAST CANCER, AND CHECKPOINT INHIBITOR RELAPSED TUMORS
Cancer types: Bladder, Breast Triple Negative, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma, Renal Cell, MSI High
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LYM 148 - SGN35-027
A SAFETY STUDY OF GROWTH FACTOR USE IN TREATMENT WITH BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 322 - CLEE011012301C
A TRIAL TO EVALUATE EFFICACY AND SAFETY OF RIBOCICLIB WITH ENDOCRINE THERAPY AS ADJUVANT TREATMENT IN PATIENTS WITH HR+HER2:- EARLY BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: Adjuvant

GI 262 - CA025-006
A STUDY OF CABIRALIZUMAB GIVEN WITH NIVOLUMAB WITH AND WITHOUT CHEMOTHERAPY IN PATIENTS WITH ADVANCED PANCREATIC CANCER
Cancer types: Pancreas/Biliary
Lines of therapy: 2nd Line Metastatic

REFMAL 407 DDU - 2015-012-00US1
A MULTI-CENTER, OPEN-LABEL, CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS OF SULFATINIB IN ADVANCED SOLID TUMORS
Cancer types: Neuroendocrine, Biliary
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MULTI 31 - 1381-0009
PLATFORM TRIAL EVALUATING SAFETY AND EFFICACY OF BI 754091 ANTI- PD-1 BASED COMBINATION THERAPIES IN PD-(L)1 NAÏVE AND PD-(L)1 PRETREATED PATIENT POPULATIONS WITH ADVANCED/METASTATIC SOLID TUMOURS.
Cancer types: Colorectal, Esophageal, Gastric, GYN, Head & Neck, Hepatocellular, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Pancreas/Biliary, Solid Tumor
Lines of therapy: 2nd Line Metastatic

LUN 398 - D9106C000002
NEOADJUVANT DURVALUMAB ALONE OR IN COMBINATION WITH NOVEL AGENTS IN RESECTABLE NON-SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: Neo-Adjuvant

REFMAL 627 DDU - 014-01
PHASE 1B OPEN-LABEL STUDY OF MK-8353 IN COMBINATION WITH SELUMETINIB (MK-5618) IN PARTICIPANTS WITH ADVANCED/METASTATIC SOLID TUMORS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma, Prostate, Renal Cell, RAS mutation, braf, NRAS
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GYN 87 - KCP-330-024
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL OF MAINTENANCE WITH SELINEXOR PLACEBO AFTER COMBINATION CHEMOTHERAPY FOR PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Cancer types: GYN
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic
**MDS 22 - ACE-536-002**
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAÎVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS THE “COMMANDS” TRIAL

Cancer types: Hematology/Other, MDS

Lines of therapy: Other

---

**LUN 404 - Array 818-202**
AN OPEN-LABEL STUDY OF ENCORAFENIB + BINIMETINIB IN PATIENTS WITH BRAFV600E-MUTANT NON-SMALL CELL LUNG CANCER

Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous

Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

---

**BRE 328 - SMX-18001**
AN OPEN, RANDOMIZED, MULTICENTER STUDY EVALUATING THE ACTIVITY OF LASOFOXIFENE RELATIVE TO FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/-HER2- BREAST CANCER WITH AN ESR1 MUTATION

Cancer types: Breast ER+

Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

---

**CLL 48 - BGB-3111-305**
A STUDY OF ZANUBRUTINIB (BGB-3111) VERSUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Cancer types: Lymphoma/Leukemia

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

---

**REFMAL 656 DDU - CO-3810-101**
A PHASE 1B/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUCITANIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH AN ADVANCED, METASTATIC SOLID TUMOR

Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Renal Cell

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

---

**MULTI 42 DDU - JTX-2011-201**
PHASE 2 MULTICENTER TRIAL OF ICOS AGONIST MONOCLONAL ANTIBODY (MAB) JTX-2011 AND A CTLA-4 INHIBITOR IN PD-1/PD-L1 INHIBITOR EXPERIENCED ADULT SUBJECTS WITH NON-SMALL CELL LUNG CANCER OR UROTHELIAL CANCER

Cancer types: Bladder, Lung NCSLC Non-Squamous, Lung NCSLC Squamous

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

---

**LYM 144 - UTX-TGR-203**
PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB IN PATIENTS WITH TREATMENT NAÏVE FOLLICULAR LYMPHOMA AND SMALL LYMPHOCYTIC LYMPHOMA

Cancer types: Lymphoma/Leukemia

Lines of therapy: 1st Line Metastatic - Locally Advanced

---

**MM 115 DDU - CC-99712-MM-001**
A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY OF CC-99712, A BCMA ANTIBODYDRUG CONJUGATE, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Cancer types: Myeloma

Lines of therapy: 3rd Line+ Metastatic

---

**REFMAL 645 DDU - PSB205-001**
A PHASE1, OPEN-LABEL, DOSE ESCALATIONAND EXPANSION STUDY TO E VALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF PSB205 IN PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS

Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell

Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
REFMAL 649 DDU - XmAb23104-01
A PHASE 1 MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF XMAB®23104 IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS (DUET-3)
Cancer types: Bladder, Breast Triple Negative, Colorectal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Renal Cell, Cervical, Nasopharyngeal, Endometrial
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 654 DDU - 74699157STM1001
A FIRST-IN-HUMAN STUDY OF THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF JNJ-74699157 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING THE KRAS G12C MUTATION
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, KRAS G12C
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 657 DDU - RBN-2397-19-001
A PHASE 1, FIRST-IN-HUMAN STUDY OF THE SAFETY, SINGLE- AND MULTIPLE-DOSE PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF ESCALATING DOSES OF RBN-2397, AN ORAL PARP7 INHIBITOR, IN PATIENTS WITH SOLID TUMORS
Cancer types: Bladder, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Cervical, ovarian, Endometrial
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 402 - 516-005
PHASE 3 STUDY OF SITRAVATINIB PLUS NIVOLUMAB VS DOCETAXEL IN PATIENTS WITH ADVANCED NON-SQUAMOUS NSCLC
Cancer types: Lung NCSLC Non-Squamous
Lines of therapy: 2nd Line Metastatic